The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.
4 affiliations
- 1Department of Endocrinology and Diabetology, University Medical Center Maribor, Maribor, Slovenia.
- 2Faculty of Medicine, University of Maribor, Maribor, Slovenia.
- 3Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia.
- 4Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Abstract
Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, offer a biologically plausible mechanism for targeting metabolic dysfunction in PMOS. This review examines clinical trial evidence on the anthropometric and metabolic effects of incretin-based therapies in this population, including a focus on women of reproductive age, who face distinct challenges related to preconception planning, treatment duration, and post-discontinuation metabolic and weight management. Available literature shows that liraglutide, semaglutide and tirzepatide produce clinically meaningful reductions in body weight, body mass index (BMI), and waist circumference, with some studies also confirming preferential effects on visceral and ectopic fat compartments. Glycaemic and insulin resistance outcomes vary across studies, while lipid and blood pressure effects remain incompletely characterized. Although emerging data suggest that higher-potency agents may yield more consistent weight-loss benefits, available PMOS-specific evidence does not establish comparative metabolic superiority among agents. Interpretation of the available evidence is limited by the predominance of short-term trials at sub-obesity doses, frequent co-administration with metformin, and the absence of phenotype-stratified data, leaving the full metabolic potential of these agents in PMOS incompletely defined. Larger, longer, and higher-dose trials are needed to fully characterize the anthropometric and metabolic potential of these agents in PMOS.
Related
- Aerobic and Aerobic-Oriented Exercise for Anthropometric, Androgen-Related, and Reproductive Endocrine Outcomes in Polyendocrine Metabolic Ovarian Syndrome (Polycystic Ovary Syndrome): A Systematic Review and Meta-Analysis
- Defining Weight‐Loss‐Independent Hepatic Effects of Incretin‐Based Therapies
- Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation
- Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study
- Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies in Type 2 Diabetes and Obesity: A Narrative Review
BibTeX
@article{koceva2026impact,
title = {{The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.}},
author = {Andrijana Koceva and Andrej Janež and Mojca Jensterle},
journal = {Diabetes, metabolic syndrome and obesity : targets and therapy},
year = {2026},
month = oct,
doi = {10.2147/dmso.s620819},
url = {https://europepmc.org/article/MED/42948675},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.
AU - Andrijana Koceva
AU - Andrej Janež
AU - Mojca Jensterle
PY - 2026
DA - 2026/10/23
JO - Diabetes, metabolic syndrome and obesity : targets and therapy
DO - 10.2147/dmso.s620819
UR - https://europepmc.org/article/MED/42948675
AB - Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide, and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide, offer a biologically plausible mechanism for targeting metabolic dysfunction in PMOS. This review examines clinical trial evidence on the anthropometric and metabolic effects of incretin-based therapies in this population, including a focus on women of reproductive age, who face distinct challenges related to preconception planning, treatment duration, and post-discontinuation metabolic and weight management. Available literature shows that liraglutide, semaglutide and tirzepatide produce clinically meaningful reductions in body weight, body mass index (BMI), and waist circumference, with some studies also confirming preferential effects on visceral and ectopic fat compartments. Glycaemic and insulin resistance outcomes vary across studies, while lipid and blood pressure effects remain incompletely characterized. Although emerging data suggest that higher-potency agents may yield more consistent weight-loss benefits, available PMOS-specific evidence does not establish comparative metabolic superiority among agents. Interpretation of the available evidence is limited by the predominance of short-term trials at sub-obesity doses, frequent co-administration with metformin, and the absence of phenotype-stratified data, leaving the full metabolic potential of these agents in PMOS incompletely defined. Larger, longer, and higher-dose trials are needed to fully characterize the anthropometric and metabolic potential of these agents in PMOS.
SN - 1178-7007
ER -